Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis

BACKGROUND: The use of standard cytotoxic chemotherapy seems to have reached a “treatment plateau”. The application of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) is a new strategy for non-small-cell lung cancer (NSCLC) therapy. We aimed to comprehensively assess the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Wenqing, Li, Yuanqi, Ye, Fei, Li, Qiangming, Zhang, Guoqing, Li, Jindong, Li, Xiangnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615333/
https://www.ncbi.nlm.nih.gov/pubmed/34964780
http://dx.doi.org/10.1097/MD.0000000000027954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615333/
https://www.ncbi.nlm.nih.gov/pubmed/34964780
http://dx.doi.org/10.1097/MD.0000000000027954

Ejemplares similares